AngioDynamics wins CE Mark for AlphaVac F18
AngioDynamics received CE Mark approval for its AlphaVac F18 system, which treats pulmonary embolism and removes thrombi and emboli.
Stay updated with breaking news from Alphavac System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AngioDynamics received CE Mark approval for its AlphaVac F18 system, which treats pulmonary embolism and removes thrombi and emboli.
Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European market ...
Regulatory approval enables entry of AlphaVac Mechanical Thrombectomy System in European market AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused
AngioDynamics this week announced it received FDA 510(k) clearance for its AlphaVac F18 system to treat pulmonary embolism (PE).
New Indication for Treatment of Pulmonary Embolism Enhances Device Utility in Critical Medical Scenarios ...